期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

硼替佐米、地塞米松加或不加沙利度胺治疗多发性骨髓瘤67例疗效分析 被引量：11

原文传递
导出
摘要 多发性骨髓瘤（MM）是一种好发于老年人的骨髓浆细胞异常增生性疾病，目前其主要治疗方法为联合化疗，现对我院2006年1月至2009年10月采用硼替佐米、地塞米松加或不加沙利度胺（VD±T）化疗方案治疗的67例MM患者的疗效进行总结和分析，以探讨其对MM的疗效及安全性。
作者 刘爱军 李利红 黄仲夏 张蕾 吴垠 李燕郴 冷芸 高文 王慧娟
机构地区 首都医科大学附属北京朝阳医院血液与肿瘤内科
出处 《中华血液学杂志》 CAS CSCD 北大核心 2010年第7期486-488,共3页 Chinese Journal of Hematology
关键词 多发性骨髓瘤 疗效分析 治疗方法 硼替佐米 沙利度胺 地塞米松 增生性疾病 骨髓浆细胞
分类号 R733.3 [医药卫生—肿瘤]
  • 相关文献

参考文献9

  • 1Dune BG,Harousseau JL,Miguel JS,et al.International uniform response criteria for multiple myeloma.Leukemia,2006,20:1467-1473.
  • 2Kyle RA,Rajkumar SV.Treatment of multiple myeloma:a comprehensive review.Clin Lymphoma Myeloma,2009,9:278-288.
  • 3Singhal S,Mehta J,Desikan R,et al.Antitumor activity of thalid-omide in refractory multiple myeloma.N Engl J Med,1999,341:1565-1571.
  • 4Dispenzieri A,Zhang L,Fonseca R,et al.Single agent borte-zomib is associated with a high response rate in patients with high risk myeloma.A phase Ⅱ study from the Eastern Cooperative Oncology Group (E2A02).Blood,2006,108:3519-3527.
  • 5Rosifiol L,Oriol A,Mateos MV,et al.Phase Ⅱ PETHEMA trial of alternating bortezomib and dexamethasone as induction regimen before autologous stem-cell transplantation in younger patients with multiple myeloma:efficacy and clinical implications of tumor response kinetics.J Clin Oncol,2007,25:4452-4458.
  • 6袁振刚,侯健,周帆,王东星,付卫军,陈玉宝,奚昊,杨盛玲.硼替佐米联合地塞米松治疗16例复发、难治性多发性骨髓瘤患者[J].中华血液学杂志,2006,27(10):653-655. 被引量：21
  • 7Li J,Zhou DB,Jiao L,et al.Bortezomib and dexamethasone therapy for newly diagnosed patients with multiple myeloma complicated by renal impairment.Clin Lymphoma Myeloma,2009,9:394-398.
  • 8易树华,王亚非,邱录贵.硼替佐米的少见毒副作用[J].中华医学杂志,2009,89(8):570-572. 被引量：3
  • 9Kim SJ,Kim K,Kim BS,et al.Bortezomib and the increased incidence of herpes zoster in patients with multiple myeloma.Clin Lymphoma Myeloma,2008,8:237-240.

二级参考文献9

  • 1王亚非,邱录贵,邹德慧,王迎,邓书会,李园,徐燕,钱林生,赵耀中.硼替佐米治疗多发性骨髓瘤后严重肺损伤二例报告并文献复习[J].白血病．淋巴瘤,2008,17(2). 被引量：12
  • 2Bross PF,Kane R,Farrell AT,et al.Approval summary for bortezomib for injection in the treatment of multiple myeloma.Clin Cancer Res,2004,10:3954 -3964.
  • 3Jagamath S,Durie BG,Wolf J,et al.Bortezomib therapy alme and in combination with dexamethasone for previously untreated symptomatic multiple myeloma.Br J Haematol,2005,129:776-783.
  • 4Richardson PG,Barlogie B,Berenson NJ,et al.A phase 2 study of bortezomib in relapsed,refraetory myeloma.N Engl J Med,2003,348:2609 -2617.
  • 5Blade J,Samson D,Reece D,et al.Criteria for evaluating disease response and progression in patients with multiple myeloma treated by high-dose therapy and haemopoietic stem cell transplantation.Myeloma Subcommittee of the EBMT.European Group for Blood and Marrow Transplant.Br J Haematol,1998,102:1115-1123.
  • 6Jagannath S,Barlogie B,Berenson J,et al.A phase 2 study of two dose of bortezomib in relapsed or refractory myeloma.Br J Haematol,2004,127:165-172.
  • 7Mitsiades N,Mitsiades CS,Richardson PG,et al.The proteasome inhibitor PS 341 potenciat essensitivity of multiple myeloma cells to conventional chemotherapeutic agents:therapeutic applications.Blood,2003,101:2377-2380.
  • 8Richardson PG,Sonneveld P,Schuster MW,et al.Bortezomib or high-dose dexamethasone for relapsed multiple myeloma.N Engl J Med,2005,352:2487-2498.
  • 9鲍立,卢锡京,张晓晖,黄晓军.不同剂量硼替佐米联合地塞米松治疗难治复发多发性骨髓瘤[J].中华医学杂志,2008,88(26):1829-1831. 被引量：7

共引文献22

同被引文献97

  • 1翟勇平,刘海宁,于亚平,宋萍,周晓钢,李锋,王学文.BLTD方案治疗24例难治复发性多发性骨髓瘤[J].中华血液学杂志,2007,28(4):270-271. 被引量：5
  • 2武永吉.多发性骨髓瘤[M]//张之南,沈悌.血液病诊断及疗效标准.3版.北京:科学出版社,2007:232-235.
  • 3Segeren CM,Sonneveld P,van der Holt B,et al.Vincristine,Doxorubicin and dexamethasone (VAD) administered as rapid intravenous infusion for first-line treatment in untreaed multiple myeloma[J].Br J Haematol,1999,105 (1):127-130.
  • 4Anderson KC.Multiple myeloma:how far have we come?[J].Mayo Clin Proc,2003,78(1):15-17.
  • 5Aghajanian C,Soignet S,Dizon DS,et al.A phase Ⅰ trial of the no2 velp roteasome inhibitor PS341 in advanced solid tumor malignancies[J].Clin Cancer Res,2002,8(8):2505-2511.
  • 6Orlowski RZ,Stinchcombe TE,Mitchell BS,et al.Phase Ⅰ trial of the p roteasome inhibitor PS2341 in patients with refractory hematologic malignancies[J].J Clin Oncol,2002,20 (22):4420-4427.
  • 7Richardson PG,Barlogie B,Berenson J,et al.A phase 2 study of bortezomib in relapsed,refractory myeloma[J].N Engl J Med,2003,348(26):2609-2617.
  • 8Jagannath S,Barlogie B,Berenson J,et al.A phase 2 study of two doses of bortezomib in relapsed or refractory myeloma[J].Br J Haematol,2004,127(2):165-72.
  • 9Richardson PG,Sonnegveld P,Schuster MW,et al.Bortezomib or high-dose dexamethasone for relapsed multip lemyeloma[J].N Engl J Med,2005,352(24):2487-2498.
  • 10Lee S J,Richardson PG,Sonne veld P,et al.Bortezomib is associated with better health-related quality of life than high-dose dexamethasone in patients with relapsed multiple myeloma:results from the APEX STUDY[J].Br J Haematol,2008,143 (4):511-519.

引证文献11

二级引证文献57

中华血液学杂志
2010年 第7期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部